181 related articles for article (PubMed ID: 33491123)
1. Employment status of patients with Charcot-Marie-Tooth type 1A.
Bjelica B; Brankovic M; Bozovic I; Palibrk A; Kacar A; Rakocevic-Stojanovic V
Acta Neurol Belg; 2022 Jun; 122(3):641-646. PubMed ID: 33491123
[TBL] [Abstract][Full Text] [Related]
2. Physical and Mental Aspects of Quality of Life in Patients With Charcot-Marie-Tooth Disease Type 1A.
Ivanovic V; Bjelica B; Palibrk A; Brankovic M; Bozovic I; Basta I; Savic A; Stojanovic VR; Kacar A
Front Neurol; 2022; 13():852150. PubMed ID: 35370888
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in hereditary neuropathy with liability to pressure palsies is as impaired as in Charcot-Marie-Tooth disease type 1A.
Bjelica B; Peric S; Bozovic I; Jankovic M; Brankovic M; Palibrk A; Rakocevic Stojanovic V
Acta Neurol Belg; 2021 Dec; 121(6):1481-1486. PubMed ID: 32335868
[TBL] [Abstract][Full Text] [Related]
4. [The application of scales and characteristics of disability in the common genotypes of Charcot-Marie-Tooth disease].
Liu X; Zhang RX; Liu L; Xie YZ; Lin ZQ; Zhao Q; Cao WQ; Zhu XY; Li XB
Zhonghua Yi Xue Za Zhi; 2021 Jan; 101(2):131-136. PubMed ID: 33455129
[No Abstract] [Full Text] [Related]
5. Neuropathic pain in patients with Charcot-Marie-Tooth type 1A.
Bjelica B; Peric S; Basta I; Bozovic I; Kacar A; Marjanovic A; Ivanovic V; Brankovic M; Jankovic M; Novakovic I; Rakocevic Stojanovic V
Neurol Sci; 2020 Mar; 41(3):625-630. PubMed ID: 31729581
[TBL] [Abstract][Full Text] [Related]
6. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.
Mannil M; Solari A; Leha A; Pelayo-Negro AL; Berciano J; Schlotter-Weigel B; Walter MC; Rautenstrauss B; Schnizer TJ; Schenone A; Seeman P; Kadian C; Schreiber O; Angarita NG; Fabrizi GM; Gemignani F; Padua L; Santoro L; Quattrone A; Vita G; Calabrese D; ; Young P; Laurà M; Haberlová J; Mazanec R; Paulus W; Beissbarth T; Shy ME; Reilly MM; Pareyson D; Sereda MW
Neuromuscul Disord; 2014 Nov; 24(11):1003-17. PubMed ID: 25085517
[TBL] [Abstract][Full Text] [Related]
7. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores.
Fridman V; Sillau S; Acsadi G; Bacon C; Dooley K; Burns J; Day J; Feely S; Finkel RS; Grider T; Gutmann L; Herrmann DN; Kirk CA; Knause SA; Laurá M; Lewis RA; Li J; Lloyd TE; Moroni I; Muntoni F; Pagliano E; Pisciotta C; Piscosquito G; Ramchandren S; Saporta M; Sadjadi R; Shy RR; Siskind CE; Sumner CJ; Walk D; Wilcox J; Yum SW; Züchner S; Scherer SS; Pareyson D; Reilly MM; Shy ME;
Neurology; 2020 Mar; 94(9):e884-e896. PubMed ID: 32047073
[TBL] [Abstract][Full Text] [Related]
8. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.
Pareyson D; Reilly MM; Schenone A; Fabrizi GM; Cavallaro T; Santoro L; Vita G; Quattrone A; Padua L; Gemignani F; Visioli F; Laurà M; Radice D; Calabrese D; Hughes RA; Solari A; ;
Lancet Neurol; 2011 Apr; 10(4):320-8. PubMed ID: 21393063
[TBL] [Abstract][Full Text] [Related]
9. Neuropathy progression in Charcot-Marie-Tooth disease type 1A.
Shy ME; Chen L; Swan ER; Taube R; Krajewski KM; Herrmann D; Lewis RA; McDermott MP
Neurology; 2008 Jan; 70(5):378-83. PubMed ID: 18227419
[TBL] [Abstract][Full Text] [Related]
10. Influence of comorbidities on the phenotype of patients affected by Charcot-Marie-Tooth neuropathy type 1A.
Ursino G; Alberti MA; Grandis M; Reni L; Pareyson D; Bellone E; Gemelli C; Sabatelli M; Pisciotta C; Luigetti M; Santoro L; Massollo L; Schenone A
Neuromuscul Disord; 2013 Nov; 23(11):902-6. PubMed ID: 23891256
[TBL] [Abstract][Full Text] [Related]
11. The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM).
Eichinger K; Burns J; Cornett K; Bacon C; Shepherd ML; Mountain J; Sowden J; Shy R; Shy ME; Herrmann DN
Neurology; 2018 Oct; 91(15):e1381-e1384. PubMed ID: 30232254
[TBL] [Abstract][Full Text] [Related]
12. Rate of Changes in CMT Neuropathy and Examination Scores in Japanese Adult CMT1A Patients.
Kitani-Morii F; Noto YI; Tsuji Y; Shiga K; Mizuta I; Nakagawa M; Mizuno T
Front Neurol; 2020; 11():626. PubMed ID: 32765395
[No Abstract] [Full Text] [Related]
13. Multidimensional evaluation is necessary to assess hand function in patients with Charcot-Marie-Tooth disease type 1A.
Reynaud V; Conforto I; Givron P; Clavelou P; Cornut-Chauvinc C; Taithe F; Pereira B; Coudeyre E
Ann Phys Rehabil Med; 2021 Mar; 64(2):101362. PubMed ID: 32109594
[TBL] [Abstract][Full Text] [Related]
14. Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure.
Mandarakas MR; Eichinger KJ; Bray P; Cornett KMD; Shy ME; Reilly MM; Ramdharry GM; Scherer SS; Pareyson D; Estilow T; McKay MJ; ; Herrmann DN; Burns J
Neurology; 2024 Feb; 102(3):e207963. PubMed ID: 38237108
[TBL] [Abstract][Full Text] [Related]
15. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.
Gess B; Baets J; De Jonghe P; Reilly MM; Pareyson D; Young P
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011952. PubMed ID: 26662471
[TBL] [Abstract][Full Text] [Related]
16. Validation of the Italian version of the Charcot-Marie-Tooth Health Index.
Pisciotta C; Ciafaloni E; Zuccarino R; Calabrese D; Saveri P; Fenu S; Tramacere I; Genovese F; Dilek N; Johnson NE; Heatwole C; Herrmann DN; Pareyson D;
J Peripher Nerv Syst; 2020 Sep; 25(3):292-296. PubMed ID: 32511835
[TBL] [Abstract][Full Text] [Related]
17. Motor performance deterioration accelerates after 50 years of age in Charcot-Marie-Tooth type 1A patients.
Tozza S; Bruzzese D; Pisciotta C; Iodice R; Esposito M; Dubbioso R; Ruggiero L; Topa A; Spina E; Santoro L; Manganelli F
Eur J Neurol; 2018 Feb; 25(2):301-306. PubMed ID: 29053907
[TBL] [Abstract][Full Text] [Related]
18. The impact of symptoms on daily life as perceived by patients with Charcot-Marie-Tooth type 1A disease.
Tozza S; Bruzzese D; Severi D; Spina E; Iodice R; Ruggiero L; Dubbioso R; Iovino A; Aruta F; Nolano M; Santoro L; Manganelli F
Neurol Sci; 2022 Jan; 43(1):559-563. PubMed ID: 33899151
[TBL] [Abstract][Full Text] [Related]
19. Recombination hot spot in a 3.2-kb region of the Charcot-Marie-Tooth type 1A repeat sequences: new tools for molecular diagnosis of hereditary neuropathy with liability to pressure palsies and of Charcot-Marie-Tooth type 1A. French CMT Collaborative Research Group.
Lopes J; LeGuern E; Gouider R; Tardieu S; Abbas N; Birouk N; Gugenheim M; Bouche P; Agid Y; Brice A
Am J Hum Genet; 1996 Jun; 58(6):1223-30. PubMed ID: 8651299
[TBL] [Abstract][Full Text] [Related]
20. A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients.
Wang W; Guedj M; Bertrand V; Foucquier J; Jouve E; Commenges D; Proust-Lima C; Murphy NP; Blin O; Magy L; Cohen D; Attarian S
PLoS One; 2017; 12(1):e0169878. PubMed ID: 28095456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
